Literature DB >> 2882992

Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man.

P J Wedlund, B J Sweetman, G R Wilkinson, R A Branch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2882992

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN： 0090-9556            Impact factor:   3.922


× No keyword cloud information.
  5 in total

1.  Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies.

Authors:  Y Zhang; R A Blouin; P J McNamara; J Steinmetz; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

2.  Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations.

Authors:  J Reviriego; L Bertilsson; J A Carrillo; A Llerena; M J Valdivielso; J Benítez
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra-individual reproducibility and occurrence of adverse events.

Authors:  W J Tamminga; J Wemer; B Oosterhuis; J Wieling; D J Touw; R A de Zeeuw; L F de Leij; J H Jonkman
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 4.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 5.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.